Allo-HSCT in CR1 beneficial for elderly AML patients with unfavorable or intermediate-risk cytogenetics

Key clinical point: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) in the first complete remission (CR1) after intensive chemotherapy (IC) offered clinical benefits in elderly patients with intermediate- or unfavorable-risk acute myeloid leukemia (AML).

Major finding: Patients who underwent allo-HSCT vs. those who did not had a significantly lower risk for relapse (hazard ratio [HR] 0.27), longer relapse-free survival (HR 0.47), and overall survival (HR 0.56), but a higher risk for nonrelapse mortality (HR 3.03; all P < .001).

Study details: This retrospective study included 507 elderly patients (age 60-70 years) with AML in CR1 after IC with intermediate or unfavorable risk cytogenetics, of which 203 patients underwent allo-HSCT.

,

Disclosures: No source of funding was identified. The authors declared no conflict of interests.

Source: Devillier R et al. Blood Adv. 2021 Sep 15. doi: 10.1182/bloodadvances.2021004435.